New pill shows promise in early leukemia trial
Disease control
Ongoing
This early-stage study tests a new daily pill, BMF-500, in adults with acute myeloid leukemia that has come back or not responded to treatment. The main goals are to check the drug's safety and find the best dose. About 35 participants will take the pill by mouth, and researchers…
Phase: PHASE1 • Sponsor: Biomea Fusion Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC